Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist, known for his expertise in spectroscopy and materials research, will bring scientific insight to the company's ongoing research and development efforts.
Uwe Perbandt, CEO of Viromed Medical AG, expressed confidence in the new appointment: "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute's Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research revolves around advanced spectroscopic methods, including Raman spectroscopy and ellipsometry, which he applies to study superconductors, quantum materials, and biological samples at large-scale facilities like PETRA III and FLASH. His work has led to over 180 publications with approximately 4,000 citations in prestigious journals such as Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Additionally, he is developing AI-supported analysis workflows for complex datasets.
This appointment underscores Viromed's commitment to leveraging top-tier scientific expertise to advance its cold plasma technology, which is used in medical applications to treat infections and promote wound healing. Cold plasma, an ionized gas at low temperatures, has shown promise in disinfecting surfaces and tissues without causing thermal damage. By integrating Prof. Rubhausen's knowledge of material properties and spectroscopy, Viromed aims to optimize its plasma devices and explore new therapeutic uses.
The Medical Advisory Board's role is to provide strategic scientific guidance, helping Viromed navigate complex research questions and validate the efficacy of its products. Prof. Rubhausen's background in analyzing biological and inorganic samples using cutting-edge techniques will be particularly valuable in understanding how cold plasma interacts with biological tissues at the molecular level.
Viromed Medical AG, listed on the stock exchange since October 2022, operates through its wholly owned subsidiary Viromed Medical GmbH. The company focuses on the distribution of innovative cold plasma technology for medical applications, with a customer base in the DACH region and beyond. The addition of Prof. Rubhausen signals a strategic move to strengthen its research capabilities and maintain a competitive edge in the rapidly evolving field of plasma medicine.
The company's technology has potential applications in dermatology, dentistry, and chronic wound care, among others. With the guidance of experts like Prof. Rubhausen, Viromed aims to accelerate the adoption of cold plasma in mainstream medicine. According to the company, the collaboration will focus on evaluating scientific questions at the intersection of material properties, spectroscopy, and cold plasma, which could lead to innovations in device design and treatment protocols.
For more information about Viromed Medical AG, visit www.viromed-medical-ag.de.
